IDEXX Laboratories, Inc. $IDXX Shares Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 42.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 884 shares of the company’s stock after purchasing an additional 265 shares during the period. Chicago Partners Investment Group LLC’s holdings in IDEXX Laboratories were worth $478,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Mutual of America Capital Management LLC grew its holdings in shares of IDEXX Laboratories by 79.6% in the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 3,766.7% in the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after purchasing an additional 113 shares in the last quarter. Plato Investment Management Ltd grew its stake in IDEXX Laboratories by 37.1% during the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after purchasing an additional 835 shares in the last quarter. Genesis Wealth Advisors LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth $215,000. Finally, ORG Wealth Partners LLC acquired a new position in shares of IDEXX Laboratories during the second quarter worth about $273,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 0.5%

IDEXX Laboratories stock opened at $633.78 on Thursday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The stock has a 50 day moving average of $638.91 and a two-hundred day moving average of $554.07. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $50.70 billion, a price-to-earnings ratio of 52.77, a PEG ratio of 4.12 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the firm earned $2.44 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Leerink Partners boosted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research report on Monday, August 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. UBS Group began coverage on IDEXX Laboratories in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 target price for the company. Finally, BTIG Research increased their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $656.50.

Insider Buying and Selling

In related news, EVP Michael Lane sold 8,411 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the sale, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sharon E. Underberg sold 5,450 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the sale, the executive vice president owned 6,156 shares of the company’s stock, valued at approximately $4,011,249.60. The trade was a 46.96% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.